Source: Annual Congress 2009 - Tuberculosis and HIV co-infection
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
C. Montaldo, B. Varghese, A. Dongre, V. Sizaire, J. Maikere, T. Reid, R. Zachariah, C. Rodrigues, G. Sotgiu, R. Centis, G. B. Migliori, E. Pontali (Genoa, Sassari, Tradate, Italy; Mumbai, India; Bruxelles, Belgium). Immunologic recovery in HIV/TB co-infected patients after anti-TB treatment. Eur Respir J 2009; 34: Suppl. 53, 3307

Member's Comments

PONTALI Emanuele - 15.09.2009 09:09
CD4
CD4 count is reported in results under 'Immunological recovery'. Viral load was not measured.

Related content which might interest you: Bedaquiline in the treatment of patients with co-infection HIV/tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly Source: Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018 Year: 2019 Impact of adverse drug reactions on treatment interruption in TB patients with and without HIV coinfection Source: ISSN=ISSN 1810-6838, ISBN=, page=190 Year: 2006 Predictors of death in patients with MDR-TB and HIV Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Features of TB/HIV co-infection and treatment outcome Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012 Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients Source: Eur Respir J, 55 (6) 1902383; 10.1183/13993003.02383-2019 Year: 2020 Timing of relapse of tuberculosis in people with co-infection (HIV/TB) Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020 Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline Source: International Congress 2019 – Tuberculosis: a public health approach Year: 2019 Adverse effects among MDR/XDR TB patients with viral hepatitus appearing during TB chemotherapy Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Impact of HIV status, CD4 count and antiretroviral treatment on tuberculosis treatment outcomes in a low-burden country Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017 Characteristics of tuberculosis patients co-infected with COVID-19 Source: Virtual Congress 2021 – Tuberculosis, COVID-19 and other comorbidities Year: 2021 Isoniazid hepatotoxicity associated with treatment of latent tuberculosis in patients on anti-TNF treatment Source: Annual Congress 2007 - Clinical tuberculosis Year: 2007 Screening and monitoring of TB infection in rheumatological patients on biologics therapy Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis Year: 2021 Bedaquiline in treatment of TB/HIV co-infection patients with extremely-drug resistance of MBT Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Multidrug-resistance tuberculosis and HIV-infected patients, the effectiveness of the treatment in Ukraine Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Characteristics of patients who interrupted anti-tuberculosis treatment Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis Year: 2008 Clinical efficacy of new anti-TB drug ²tubelon² during complex chemotherapy in patients with first-time diagnosed destuctive pulmonary TB Source: Eur Respir J 2006; 28: Suppl. 50, 8s Year: 2006 Primary drug resistance in HIV/TB patients Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts Year: 2011